Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

462.46 -0.44 (-0.09%)

Streaming Delayed Price Updated: 9:59 AM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Which S&P500 stocks have an unusual volume on Wednesday? ↗

August 06, 2025

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.

Via Chartmill

Which S&P500 stocks are moving on Wednesday? ↗

August 06, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Strong Affordable Growth Pick with Solid Fundamentals ↗

August 06, 2025

Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors.

Via Chartmill

7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip ↗

August 06, 2025

There's more good news than bad news for this big biotech stock.

Via The Motley Fool

Topics Earnings

Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity ↗

August 05, 2025

Via Stocktwits

Market Monitor News August 06 BMO - Wall Street Slides as Services Sector Falters, but Palantir Rockets Past Expectations ↗

August 06, 2025

A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.

Via Chartmill

Topics Economy

Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today

August 05, 2025

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial....

Via StockStory

Topics Artificial Intelligence

Top S&P500 movers in Tuesday's session ↗

August 05, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Via Chartmill

Weakness In Vertex Stock Seen As Buying Opportunity ↗

August 05, 2025

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.

Via Benzinga

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results ↗

August 05, 2025

Via Benzinga

Stock Market Rollercoaster: Wall Street Navigates Sharp Swings and Rebounds in Early August

August 05, 2025

The financial markets have been on a tumultuous ride in early August 2025, experiencing a dramatic "see-saw" pattern that has left investors both wary and hopeful. Following a sharp decline at the...

Via MarketMinute

Topics Artificial Intelligence Economy Government

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 05, 2025

Via Benzinga

Which S&P500 stocks have an unusual volume on Tuesday? ↗

August 05, 2025

Let's have a look at the S&P500 stocks with an unusual volume in today's session.

Via Chartmill

Which S&P500 stocks are moving on Tuesday? ↗

August 05, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.

Via Chartmill

What's going on in today's session: S&P500 gap up and gap down stocks ↗

August 05, 2025

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.

Via Chartmill

Assessing Vertex Pharmaceuticals: Insights From 9 Financial Analysts ↗

August 05, 2025

Via Benzinga

Discover the top S&P500 movers in Tuesday's pre-market session. ↗

August 05, 2025

Stay updated with the S&P500 stocks that are on the move in today's pre-market session.

Via Chartmill

These stocks are moving in today's pre-market session ↗

August 05, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

August 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 05, 2025

Via Benzinga

Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗

August 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 04, 2025

Via Benzinga

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993 ↗

August 04, 2025

Vertex Pharmaceuticals announces financial results for the second quarter after the market close on Monday. Here's a rundown of the report.

Via Benzinga

Which stocks are moving after the closing bell on Monday? ↗

August 04, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Stock Plummets 13% After Discontinuing VX-993 Despite Q2 Earnings Beat ↗

August 04, 2025

Vertex Q2 2025 earnings beat estimates, but stock dropped 13% after discontinuing acute pain drug VX-993. Focus remains on CF and other key programs.

Via Chartmill

Topics Earnings

Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat ↗

August 04, 2025

Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.

Via Investor's Business Daily

Topics ETFs

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%

August 04, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full...

Via StockStory

Topics Earnings

Vertex Reports Second Quarter 2025 Financial Results

August 04, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

August 04, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

August 04, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.